Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for sparsentan

  1. Sparsentan for treating primary IgA nephropathy (TA1074)

    Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Last updated
    9 October 2025
    View recommendations

    Sections for TA1074

  2. Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

    In development Reference number: GID-TA11662 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development

  3. Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]

    Awaiting development Reference number: GID-TA10867 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease

    New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.

    News
    Last updated
    27 May 2025